Literature DB >> 30575935

Oltipraz attenuates the progression of heart failure in rats through inhibiting oxidative stress and inflammatory response.

Y Tang1, M Guo, X-Y Ma, W-P Sun, M-H Hao, H-Y Zhu.   

Abstract

OBJECTIVE: To evaluate the effect of oltipraz (OPZ) on isoproterenol-induced heart failure (HF) and heart function. We also explore the underlying molecular mechanism of OPZ.
MATERIALS AND METHODS: The rats were randomly divided into four groups, including normal control group, isoproterenol (ISO) group, ISO +100 mg/kg OPZ group, and OPZ group. Hemodynamic parameters, such as left-ventricular systolic pressure, were statistically analyzed. Besides, plasma levels of brain natriuretic peptide (BNP), pro-inflammatory cytokines and antioxidant markers were assessed by using enzyme-linked immunosorbent assay (ELISA). Moreover, histopathological examination was applied to assess the degree of cardiac interstitial fibrosis.
RESULTS: OPZ could statistically improve the hemodynamic parameters of the heart function, and could also obviously attenuate cardiac interstitial fibrosis in ISO-induced HF rats when compared with the ISO group. Besides, plasma level of BNP in ISO +100 mg/kg OPZ group dramatically decreased in comparison with that of ISO group. Moreover, compared with ISO group, OPZ treatment significantly reduced the levels of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). Moreover, OPZ treatment remarkably increased the levels of antioxidant markers such as superoxide dismutase (SOD) and glutathione peroxidase (GPx) in ISO-induced HF rats.
CONCLUSIONS: OPZ administration may provide experimental evidence for the possible effect of OPZ on isoproterenol-induced heart failure in rats. Moreover, OPZ administration may have potential utility for the treatment of heart failure.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30575935     DOI: 10.26355/eurrev_201812_16661

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  The deleterious role of the prostaglandin E2 EP3 receptor in angiotensin II hypertension.

Authors:  Timothy D Bryson; Teja S Pandrangi; Safa Z Khan; Jiang Xu; Tengis S Pavlov; Pablo A Ortiz; Edward Peterson; Pamela Harding
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-03-06       Impact factor: 4.733

2.  Oltipraz Prevents High Glucose-Induced Oxidative Stress and Apoptosis in RSC96 Cells through the Nrf2/NQO1 Signalling Pathway.

Authors:  Zengxin Jiang; Mengxuan Bian; Jingping Wu; Defang Li; Lei Ding; Qingmin Zeng
Journal:  Biomed Res Int       Date:  2020-06-23       Impact factor: 3.411

3.  Analgesic and Antidepressant Effects of Oltipraz on Neuropathic Pain in Mice by Modulating Microglial Activation.

Authors:  Andrés Felipe Díaz; Sara Polo; Núria Gallardo; Sergi Leánez; Olga Pol
Journal:  J Clin Med       Date:  2019-06-21       Impact factor: 4.241

4.  N-Acetylcysteine Slows Down Cardiac Pathological Remodeling by Inhibiting Cardiac Fibroblast Proliferation and Collagen Synthesis.

Authors:  Jin Zhou; Jing Xu; Shan Sun; Mengyuan Guo; Peng Li; Aijuan Cheng
Journal:  Dis Markers       Date:  2021-11-26       Impact factor: 3.434

5.  Modulation of Oxidative Stress and Inflammation in the Aged Lacrimal Gland.

Authors:  Rodrigo G de Souza; Zhiyuan Yu; Humberto Hernandez; Claudia M Trujillo-Vargas; Andrea Lee; Kelsey E Mauk; Jiyang Cai; Milton R Alves; Cintia S de Paiva
Journal:  Am J Pathol       Date:  2020-11-04       Impact factor: 4.307

6.  Disruption of STAT6 Signal Promotes Cardiac Fibrosis Through the Mobilization and Transformation of CD11b+ Immature Myeloid Cells.

Authors:  Weiwei Zhang; Baoling Zhu; Suling Ding; Xiangfei Wang; Jian Wu; Xiaowei Zhu; Yunzeng Zou; Junbo Ge; Minghong Tong; Xiangdong Yang
Journal:  Front Physiol       Date:  2020-10-22       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.